Papillary meningioma of the cerebellum

Summary

Papillary meningioma of the cerebellum (MONDO:0003261) is a disease. A subtype of cerebellar neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	papillary meningioma of the cerebellum
Mondo ID	MONDO:0003261
DOID	DOID:5057
NCIT	C5270
UMLS	C1332902
MedGen	234109
GARD	0023429
Anatomy (UBERON)	UBERON:0002037
Is cancer (heuristic)	no

Also known as: cerebellum papillary meningioma · papillary meningioma of cerebellum · papillary meningioma of the cerebellum

Disease family

This is a subtype of cerebellar neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › brain disorder › cerebellar disorder › cerebellar neoplasm › papillary meningioma of the cerebellum

Related subtypes (7): cerebellar astrocytoma, adult cerebellar neoplasm, childhood cerebellar neoplasm, cerebellar liponeurocytoma, medulloblastoma, cancer of cerebellum, benign neoplasm of cerebellum

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.